Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
30 March 2023 - 10:00PM
Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patient lives by
developing and commercializing innovative products across a range
of therapeutic areas, today announced that it has entered into a
platform research evaluation collaboration and option agreement
with Regeneron Pharmaceuticals, Inc. Under the terms of the
agreement, Xeris will use its proprietary drug-formulation
platform, XeriJect™, to develop ultra-highly concentrated,
ready-to-use, small volume subcutaneous injections of two
undisclosed monoclonal antibodies (mAbs) developed by Regeneron.
Xeris will receive an upfront payment and potential milestone
payments for preclinical achievements. Regeneron has an option to
commercially license the Xeris technology for such molecules and
nominate additional molecules for reformulation and potential
commercialization. Specific financial terms of the agreement were
not disclosed.
“We are excited to be working with Regeneron on a platform
collaboration basis, which builds on our prior feasibility studies
and reflects the significant progress and investment we have been
making into the development of XeriJect™,” said Paul R. Edick,
Chairman and CEO of Xeris Biopharma. “Through our novel
drug-formulation platform, we aim to provide our biologic
development collaborators with the competitive advantage of
delivering a significantly improved patient and provider experience
through stable, ready-to-use, ultra-highly concentrated,
small-volume subcutaneous injection formulations. This agreement
with Regeneron is another in a series of collaborations Xeris has
recently undertaken with top pharmaceutical and biotechnology
companies.”
About XeriJect™
Xeris’ drug-delivery system, XeriJect, provides innovative,
ready-to-use, viscoelastic pharmaceutical suspensions that have the
potential to improve drug delivery, lower treatment burden and
improve patients' lives across a broad range of therapeutic
categories. XeriJect suspensions maximize drug loadings at
>450mg/mL, enable small volume subcutaneous injections, do not
settle on storage and are ready-to-use. The suspensions use
FDA-approved excipients and leverage known manufacturing processes.
XeriJect formulation technology is well suited for drugs and
biologics including large molecules such as proteins, monoclonal
antibodies, and vaccines. The technology is protected by an
extensive patent estate, trade secrets and know-how, and it is
available for licensing.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patients’ lives by developing and
commercializing differentiated and innovative products across a
range of therapies. Xeris has three commercially available
products: Gvoke®, a ready-to-use liquid glucagon for the treatment
of severe hypoglycemia; Keveyis®, a proven therapy for primary
periodic paralysis; and Recorlev® for the treatment of endogenous
Cushing’s syndrome. Xeris has a diverse pipeline of development and
partnered programs using its formulation sciences, XeriSol™ and
XeriJect™, to support long-term product development and commercial
success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on
Twitter, LinkedIn, or Instagram.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Xeris Biopharma Holdings, Inc., including
the development of a sub-cutaneous formulation of undisclosed
monoclonal (mAb), the market and therapeutic potential of Xeris’
products and product candidates, expectations regarding clinical
data or results from planned clinical trials, the timing of
clinical trials, the timing or likelihood of regulatory approval
and commercialization of its product candidates, the timing or
likelihood of expansion into additional markets, the potential
utility of its proprietary formulation technology platforms, the
potential to receive milestone payments if Regeneron exercises its
option and other statements containing the words “will,” “would,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on
numerous assumptions and assessments made in light of Xeris’
experience and perception of historical trends, current conditions,
business strategies, operating environment, future developments,
and other factors it believes appropriate. By their nature,
forward-looking statements involve known and unknown risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. Various factors could
cause Xeris’ actual results, performance or achievements, industry
results and developments to differ materially from those expressed
in or implied by such forward-looking statements, including the
impact of COVID-19 on our business operations and clinical
activities, our ability to fund our product development programs or
commercialization efforts, and whether our products will achieve
and maintain market acceptance. No assurance can be given that our
expectations will be realized and persons reading this
communication are, therefore, cautioned not to place undue reliance
on these forward-looking statements. Additional information about
economic, competitive, governmental, technological, and other
factors that may affect Xeris is set forth in the "Risk Factors"
section of the most recently filed Quarterly Report on Form 10-K
filed with the U.S. Securities and Exchange Commission, the
contents of which are not incorporated by reference into, nor do
they form a part of, this communication. Forward-looking statements
in this communication are based upon information available to
Xeris, as of the date of this communication and, while believed to
be reasonable, actual results may differ materially. Subject to any
obligations under applicable law, Xeris does not undertake any
obligation to update any forward-looking statement whether as a
result of new information, future developments or otherwise, or to
conform any forward-looking statement to actual results, future
events, or to changes in expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230330005239/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com 312-736-1237
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2023 to Apr 2024